UK updates guidance for MoM hip patient follow-up with extended blood and MRI screening regime
This article was originally published in Clinica
Executive Summary
An estimated 49,000 UK patients with metal-on-metal (MoM) hip implants could face a life-time of annual check-ups after the country's Medicines and Healthcare products Regulatory Agency (MHRA) updated its April 2010 guidance on the follow-up protocol for these devices. The new guidance, which introduces a tighter blood testing and diagnostic imaging regime, is in response to growing concerns related to the risks posed by debris from wear and tear of these types of orthopaedic implants over time.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.